|
1
|
Bolgiano B, Moran E, Beresford NJ, Gao F, Care R, Desai T, Nordgren IK, Rudd TR, Feavers IM, Bore P, Patni S, Gavade V, Mallya A, Kale S, Sharma P, Goel SK, Gairola S, Hattarki S, Avalaskar N, Sarma AD, LaForce M, Ravenscroft N, Khandke L, Alderson MR, Dhere RM, Pisal SS. Evaluation of Critical Quality Attributes of a Pentavalent (A, C, Y, W, X) Meningococcal Conjugate Vaccine for Global Use. Pathogens 2021; 10:928. [PMID: 34451392 PMCID: PMC8400332 DOI: 10.3390/pathogens10080928] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Revised: 07/09/2021] [Accepted: 07/19/2021] [Indexed: 11/16/2022] Open
Abstract
Towards achieving the goal of eliminating epidemic outbreaks of meningococcal disease in the African meningitis belt, a pentavalent glycoconjugate vaccine (NmCV-5) has been developed to protect against Neisseria meningitidis serogroups A, C, Y, W and X. MenA and X polysaccharides are conjugated to tetanus toxoid (TT) while MenC, Y and W polysaccharides are conjugated to recombinant cross reactive material 197 (rCRM197), a non-toxic genetic variant of diphtheria toxin. This study describes quality control testing performed by the manufacturer, Serum Institute of India Private Limited (SIIPL), and the independent control laboratory of the U.K. (NIBSC) on seven clinical lots of the vaccine to ensure its potency, purity, safety and consistency of its manufacturing. In addition to monitoring upstream-manufactured components, samples of drug substance, final drug product and stability samples were evaluated. This paper focuses on the comparison of the vaccine's critical quality attributes and reviews key indicators of its stability and immunogenicity. Comparable results were obtained by the two laboratories demonstrating sufficient levels of polysaccharide O-acetylation, consistency in size of the bulk conjugate molecules, integrity of the conjugated saccharides in the drug substance and drug product, and acceptable endotoxin content in the final drug product. The freeze-dried vaccine in 5-dose vials was stable based on molecular sizing and free saccharide assays. Lot-to-lot manufacturing consistency was also demonstrated in preclinical studies for polysaccharide-specific IgG and complement-dependent serum bactericidal activity for each serogroup. This study demonstrates the high quality and stability of NmCV-5, which is now undergoing Phase 3 clinical trials in Africa and India.
Collapse
Affiliation(s)
- Barbara Bolgiano
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Eilís Moran
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Nicola J. Beresford
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Fang Gao
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Rory Care
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Trusha Desai
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Ida Karin Nordgren
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Timothy R. Rudd
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Ian M. Feavers
- National Institute for Biological Standards and Control, South Mimms, Potters Bar EN6 3QG, UK; (E.M.); (N.J.B.); (F.G.); (R.C.); (T.D.); (I.K.N.); (T.R.R.); (I.M.F.)
| | - Prashant Bore
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Sushil Patni
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Vinay Gavade
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Asha Mallya
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Sameer Kale
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Pankaj Sharma
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Sunil K. Goel
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Sunil Gairola
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Suhas Hattarki
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Nikhil Avalaskar
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Annamraju D. Sarma
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Marc LaForce
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Neil Ravenscroft
- Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7701, South Africa;
| | - Lakshmi Khandke
- Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA; (L.K.); (M.R.A.)
| | - Mark R. Alderson
- Center for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA; (L.K.); (M.R.A.)
| | - Rajeev M. Dhere
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| | - Sambhaji S. Pisal
- Serum Institute of India Pvt. Ltd., Hadapsar, Pune 411028, India; (P.B.); (S.P.); (V.G.); (A.M.); (S.K.); (P.S.); (S.K.G.); (S.G.); (S.H.); (N.A.); (A.D.S.); (M.L.); (R.M.D.); (S.S.P.)
| |
Collapse
|
|
2
|
Wang H, Liang K, Kong Q, Liu Q. Immunization with outer membrane vesicles of avian pathogenic Escherichia coli O78 induces protective immunity in chickens. Vet Microbiol 2019; 236:108367. [PMID: 31500727 DOI: 10.1016/j.vetmic.2019.07.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2019] [Revised: 07/08/2019] [Accepted: 07/20/2019] [Indexed: 01/31/2023]
Abstract
Avian pathogenic Escherichia coli (APEC) typically causes colibacillosis and is a major concern for the poultry industry and public health. As a vaccine platform, the outer membrane vesicles (OMVs) derived from various gram-negative bacteria and even some gram-positive bacteria have been reported to be immunogenic in laboratories or upon commercial usage worldwide. Here, we purified OMVs from APEC serotype O78 strain by ultracentrifugation and gradient isolation. By SDS-PAGE and LC-MS/MS analysis, the 20 most abundant proteins located on OMVs were identified and analyzed; the lipopolysaccharide (LPS) profiles of OMVs were not different from those of the bacteria. Moreover, three groups of chickens were immunized with OMV-, outer membrane protein (OMP)- and PBS, with the latter two serving as positive and negative controls, respectively. By analyzing the anti-OMP and anti-LPS IgG titers stimulated by the tested vaccine candidates, the macrophage opsonophagocytic activity and the bactericidal activity mediated by serum antibodies in vaccinated chickens, we found that the OMV-vaccinated chicken group was superior to the two other groups. These findings were confirmed by additional chicken challenge tests, in which all OMV-vaccinated group chickens obtained complete protection but those of the other two groups were barely protected. Our data demonstrate that native APEC O78 OMVs can induce protective immunity in chickens and therefore be used as a candidate vaccine for APEC serotype O78 strain infections.
Collapse
Affiliation(s)
- Haoju Wang
- College of Veterinary Science and Technology, Southwest University, Chongqing, 400700, China; Chongqing Engineering Research Center for Herbivores Resource Protection and Utilization, Chongqing, 400700, China
| | - Kang Liang
- College of Veterinary Science and Technology, Southwest University, Chongqing, 400700, China
| | - Qingke Kong
- College of Veterinary Science and Technology, Southwest University, Chongqing, 400700, China
| | - Qing Liu
- College of Veterinary Science and Technology, Southwest University, Chongqing, 400700, China; Chongqing Engineering Research Center for Herbivores Resource Protection and Utilization, Chongqing, 400700, China.
| |
Collapse
|
|
3
|
Norheim G, Mueller JE, Njanpop-Lafourcade BM, Delrieu I, Findlow H, Borrow R, Xie O, Nagaputra J, Ramasamy R, Dold C, Tamekloe TA, Rollier CS, Watt H, Kere AB, Næss LM, Pollard AJ. Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007. Vaccine 2018; 36:1297-1303. [DOI: 10.1016/j.vaccine.2018.01.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2016] [Revised: 01/10/2018] [Accepted: 01/11/2018] [Indexed: 12/12/2022]
|
|
4
|
Acevedo R, Zayas C, Norheim G, Fernández S, Cedré B, Aranguren Y, Cuello M, Rodriguez Y, González H, Mandiarote A, Pérez M, Hernández M, Hernández-Cedeño M, González D, Brorson SH, Rosenqvist E, Naess L, Tunheim G, Cardoso D, García L. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa. Pharmacol Res 2017; 121:194-201. [PMID: 28495657 DOI: 10.1016/j.phrs.2017.04.030] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 04/13/2017] [Accepted: 04/29/2017] [Indexed: 11/30/2022]
Abstract
Meningococcal disease is caused mainly by serogroups A, B, C, Y, W of N. meningitidis. However, numerous cases of meningitis caused by serogroup X N. meningitidis (MenX) have recently been reported in several African countries. Currently, there are no licensed vaccines against this pathogen and most of the MenX cases have been caused by meningococci from clonal complex (c.c) 181. Detergent extracted meningococcal outer membrane vesicle (dOMV) vaccines have previously shown to be safe and effective against epidemics of serogroup B meningococcal disease in all age groups. The aim of this work is therefore to obtain, characterize and evaluate the vaccine potential of dOMVs derived from a MenX strain (OMVx). Three experimental lots of OMVx were prepared by deoxycholate extraction from the MenX strain BF 2/97. Size and morphology of the vesicles was determined by Dynamic Light Scattering and electron microscopy, whereas the antigenic composition was characterized by gel electrophoresis and immunoblotting. OMVx were thereafter adsorbed to aluminium hydroxide (OMVx/AL) and two doses of OMVx were administered s.c. to groups of Balb/c mice three weeks apart. The immunogenicity and functional antibody activities in sera were evaluated by ELISA (anti-OMVx specific IgG responses) and serum bactericidal activity (SBA) assay. The size range of OMVx was shown to be between 90 and 120nm, whereas some of the antigens detected were the outer membrane proteins PorA, OpcA and RmpM. The OMVx/AL elicited high anti-OMVx antibody responses with bactericidal activity and no bactericidal activity was observed in the control group of no immunised mice. The results demonstrate that OMVx are immunogenic and could form part of a future vaccine to prevent the majority of meningococcal disease in the African meningitis belt.
Collapse
Affiliation(s)
| | - Caridad Zayas
- Finlay Institute, P.O. Box 16000, La Lisa, Havana, Cuba
| | | | | | - Barbara Cedré
- Finlay Institute, P.O. Box 16000, La Lisa, Havana, Cuba
| | | | - Maribel Cuello
- Faculty of Engineering and Technology, Techinal University "Luis Vargas Torres", Emeralds, Ecuador
| | | | | | | | | | | | | | | | | | | | | | - Gro Tunheim
- Norwegian Institute of Public Health, Oslo, Norway
| | | | - Luis García
- Finlay Institute, P.O. Box 16000, La Lisa, Havana, Cuba
| |
Collapse
|
|
5
|
Kristiansen PA, Jørgensen HJ, Caugant DA. Serogroup A meningococcal conjugate vaccines in Africa. Expert Rev Vaccines 2015; 14:1441-58. [PMID: 26358167 DOI: 10.1586/14760584.2015.1084232] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Serogroup A meningococcal epidemics have been a recurrent public health problem, especially in resource-poor countries of Africa. Recently, the administration in mass vaccination campaigns of a single dose of the monovalent meningococcal conjugate vaccine, MenAfriVac, to the 1-29 year-old population of sub-Saharan Africa has prevented epidemics of meningitis caused by serogroup A Neisseria meningitidis. This strategy has also been shown to provide herd protection of the non-vaccinated population. Development of meningococcal conjugate vaccines covering other serogroups and enhanced use of the pneumococcal and Haemophilus influenzae type b conjugate vaccines must be pursued to fully control bacterial meningitis in sub-Saharan Africa.
Collapse
Affiliation(s)
- Paul A Kristiansen
- a 1 WHO Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
| | - Hannah J Jørgensen
- a 1 WHO Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
| | - Dominique A Caugant
- a 1 WHO Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway.,b 2 Faculty of medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway
| |
Collapse
|